A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary) ; Omalizumab
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Acronyms EVEREST
- Sponsors Sanofi
- 20 Jan 2025 Status changed from active, no longer recruiting to completed.
- 03 Sep 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 11 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.